Furthermore, Nisebita et al. showed that the miR‐371‐3p/peroxiredoxin 6 axis contributed to drug tolerance by modulating redox homeostasis, suggesting combining current cancer therapies with a ROS inducer as a potential strategy for delaying acquired drug resistance (Sahu et al,2016). Here, PRDX6 is linked to cancer.